scholarly journals Long-acting drugs and formulations for the treatment and prevention of HIV infection

2021 ◽  
Vol 57 (1) ◽  
pp. 106220
Author(s):  
Charles Flexner ◽  
Andrew Owen ◽  
Marco Siccardi ◽  
Susan Swindells
2015 ◽  
Vol 10 (4) ◽  
pp. 278-281 ◽  
Author(s):  
Vikram Arya ◽  
Stanley Au ◽  
Yodit Belew ◽  
Peter Miele ◽  
Kimberly Struble

2018 ◽  
Vol 11 (5) ◽  
pp. 507-517 ◽  
Author(s):  
Laura Benítez-Gutiérrez ◽  
Vicente Soriano ◽  
Silvia Requena ◽  
Ana Arias ◽  
Pablo Barreiro ◽  
...  

Author(s):  
Paul Thoueille ◽  
Eva Choong ◽  
Matthias Cavassini ◽  
Thierry Buclin ◽  
Laurent A Decosterd

Abstract The long-acting antiretroviral cabotegravir and rilpivirine combination has just received FDA, EMA and Health Canada approval. This novel drug delivery approach is about to revolutionize the therapy of people living with HIV, decreasing the 365 daily pill burden to only six intramuscular injections per year. In addition, islatravir, a first-in-class nucleoside reverse transcriptase translocation inhibitor, is intended to be formulated as an implant with a dosing interval of 1 year or more. At present, long-acting antiretroviral therapies (LA-ARTs) are given at fixed standard doses, irrespectively of the patient’s weight and BMI, and without consideration for host genetic and non-genetic factors likely influencing their systemic disposition. Despite a few remaining challenges related to administration (e.g. pain, dedicated medical procedure), the development and implementation of LA-ARTs can overcome long-term adherence issues by improving patients’ privacy and reducing social stigma associated with the daily oral intake of anti-HIV treatments. Yet, the current ‘one-size-fits-all’ approach does not account for the recognized significant inter-individual variability in LA-ART pharmacokinetics. Therapeutic drug monitoring (TDM), an important tool for precision medicine, may provide physicians with valuable information on actual drug exposure in patients, contributing to improve their management in real life. The present review aims to update the current state of knowledge on these novel promising LA-ARTs and discusses their implications, particularly from a clinical pharmacokinetics perspective, for the future management and prevention of HIV infection, issues of ongoing importance in the absence of curative treatment or an effective vaccine.


2020 ◽  
Vol 16 (7) ◽  
pp. 551-564
Author(s):  
Piyanuch Wonganan ◽  
Wacharee Limpanasithikul ◽  
Suree Jianmongkol ◽  
Stephen J. Kerr ◽  
Kiat Ruxrungtham

JAMA ◽  
2020 ◽  
Vol 324 (16) ◽  
pp. 1651 ◽  
Author(s):  
Michael S. Saag ◽  
Rajesh T. Gandhi ◽  
Jennifer F. Hoy ◽  
Raphael J. Landovitz ◽  
Melanie A. Thompson ◽  
...  

2020 ◽  
Vol 15 (1) ◽  
pp. 19-26 ◽  
Author(s):  
Meredith E. Clement ◽  
Ryan Kofron ◽  
Raphael J. Landovitz

JAMA ◽  
2018 ◽  
Vol 320 (4) ◽  
pp. 379 ◽  
Author(s):  
Michael S. Saag ◽  
Constance A. Benson ◽  
Rajesh T. Gandhi ◽  
Jennifer F. Hoy ◽  
Raphael J. Landovitz ◽  
...  

2020 ◽  
Vol 15 (1) ◽  
pp. 61-65 ◽  
Author(s):  
Mario R. Sampson ◽  
Stephanie B. Troy ◽  
Yodit Belew ◽  
Vikram Arya ◽  
Kimberly A. Struble

Sign in / Sign up

Export Citation Format

Share Document